FAST NEWS: WuXi XDC’s profit surges on growth in ADC market
The latest: WuXi XDC Cayman Inc. (2268.HK) announced Thursday that it expects to report its net profit last year jumped more than 80% from 2022, while its adjusted net profit and…
WuXi Biologics hatches new baby with ADC drug unit IPO
The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs Key Takeaways: WuXi XDC has…
Investors Bet Big on Cancer Drug Infant Duality Biologics and Its Rockstar Founder
Company has raised $120 million in 18 months from A-list investors including Eli Lilly and domestic heavyweight WuXi Biologics Key takeaways Duality Biologics’ new $90 million funding just 18 months…
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
BRIEF: WuXi XDC’s revenue, profit jump in 2024
2268.HK
-
Yan Palace flies back to profit growth as revenue sags
1497.HK
-
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
BRIEF: Shanghai Chicmax’s profit surges nearly 70%, growth slows in second half
2145.HK
- Mixue pours up strong growth in China’s overheated bubble tea market
